Novocure reports preliminary FY2022 net revenue $537.8M (+1% YoY); LUNAR study meets primary endpoint

NovoCure Ltd

2022-FY EPS reported -$0.88 revenue$537,840,000

FY2022 net revenue $537.8M, +1% YoY; Q4 net revenue $128.4M, with US $98.6M, EMEA $17.0M, Japan $7.9M, Greater China $4.9M.
Cash, equivalents and short-term investments $969.4M as of Dec 31, 2022.
3,430 active patients; 1,373 prescriptions received in Q4 (North America 956, EMEA 312, Japan 105).
LUNAR study met primary endpoint: significant overall survival benefit with TTFields + immune checkpoint inhibitors in NSCLC.
New thinner/lighter arrays launched in Europe under limited market release; Health Canada approved Optune for GBM.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NovoCure Ltd reported for the quarter and year ended December 31, 2022 results: revenue $537.8 million.

Period: for the quarter and year ended December 31, 2022
Revenue: $537.8 million
Result: preliminary results

Exact text from the filing

--- EX-99.1 (EX-99.1) --- Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update Preliminary full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-23-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.